EGFR and breast carcinoma: The study by Borah at et al. (2020) aimed to inhibit the Hh/Gli-EGFR signaling pathway in breast cancer by co-delivering curcumin and a Hh/Gli small molecule antagonist GANT61 via polymeric nanoparticles.